Sat.Jan 07, 2023 - Fri.Jan 13, 2023

article thumbnail

5 questions facing emerging biotech in 2023

Bio Pharma Dive

Investors expect another lackluster year in IPOs, while company restructurings look set to continue as biotech executives try to conserve cash

271
271
article thumbnail

Health Canada gives approval to Enhertu for breast cancer treatment

Pharmaceutical Technology

Health Canada has granted approval to Enhertu (trastuzumab deruxtecan) to treat unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

HR 257
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Holiday Surprise; FTC Published Its Health Products Compliance Guidance

The FDA Law Blog

By Riëtte van Laack & Ricardo Carvajal — On Dec. 20, 2022, FTC announced the publication of its Health Products Compliance Guidance (“new Guidance”).

article thumbnail

AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

The Pharma Data

Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome’s Discovery Engine – Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties.

article thumbnail

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

article thumbnail

5 FDA decisions to watch in the first quarter

Bio Pharma Dive

An Alzheimer’s drug from Eli Lilly, BioMarin’s hemophilia gene therapy and a new type of breast cancer treatment are among the top decisions on the agency’s docket through the end of March

article thumbnail

Are we entering the era of biologics for COPD?

Pharmaceutical Technology

In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma.

Antibody 242

More Trending

article thumbnail

JPM23, Day 1: BMS touts new launches as patent cliff looms; Regeneron's Eylea sales disappoint

Fierce Pharma

JPM23, Day 1: BMS touts new launches as patent cliff looms; Regeneron's Eylea sales disappoint. esagonowsky. Mon, 01/09/2023 - 09:55

Sales 110
article thumbnail

5 questions facing gene therapy in 2023

Bio Pharma Dive

Buoyed by recent approvals, the field faces a pivotal year that’s likely to bring new treatments as well as more challenges

article thumbnail

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

Pharmaceutical Technology

On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D).

Insulin 207
article thumbnail

AstraZeneca's Tezspire receives approval for asthma treatment

Pharma Times

Green light for new asthma pen which offers self-administration option across the EU

112
112
article thumbnail

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

article thumbnail

BioNTech to acquire AI specialist InstaDeep: ‘Our aim is to be a technology company where AI is seamlessly integrated into all aspects of our work’

BioPharma Reporter

German mRNA pioneer BioNTech will acquire InstaDeep, an artificial intelligence and machine learning specialist, for around Â362m ($439m): pledging to incorporate rapidly evolving AI capabilities into its research, drug discovery, manufacturing and deployment processes. Bio Developments

article thumbnail

JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas

Bio Pharma Dive

The FDA commissioner shared advice for drugmakers at the J.P. Morgan Healthcare conference, while venture investors cautioned of a coming funding crunch for young biotechs

281
281
article thumbnail

AstraZeneca starts 2023 with $1.8 billion cardiovascular acquisition

Pharmaceutical Technology

AstraZeneca has announced its plans to acquire US-based biopharmaceutical company CinCor in a $1.8 billion deal, signalling the company’s interest in renal and cardiovascular therapies. Last August, CinCor Pharma raised $258.7

article thumbnail

Pheno and UCB reveal neurodegenerative disease programme agreement

Pharma Times

Global preclinical programme has the potential for disease modifying therapeutics

110
110
article thumbnail

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

article thumbnail

JPM23: Pfizer entering the 'most important' 18-month stretch in company history, CEO says

Fierce Pharma

JPM23: Pfizer entering the 'most important' 18-month stretch in company history, CEO says. esagonowsky. Tue, 01/10/2023 - 08:51

104
104
article thumbnail

JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor

Bio Pharma Dive

Executives at the two pharmas talked up their rival autoimmune disease drugs at the J.P. Morgan Healthcare Conference, while Prime Medicine’s CEO pondered a busy future

Drugs 268
article thumbnail

US FDA approves Eisai-Biogen’s antibody for Alzheimer’s

Pharmaceutical Technology

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD).

article thumbnail

SIFI and Avanzanite announce AKANTIOR agreement

Pharma Times

Partnership offers treatment access to hundreds of patients across several European countries

109
109
article thumbnail

JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amyrt buyout

Fierce Pharma

JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amyrt buyout. esagonowsky. Mon, 01/09/2023 - 08:14

102
102
article thumbnail

5 questions facing the pharma industry in 2023

Bio Pharma Dive

Drug price reforms and regulatory scrutiny present challenges for large drugmakers, although successes in Alzheimer’s and obesity have brought new opportunities, too

Drugs 264
article thumbnail

AstraZeneca to buy US-based CinCor Pharma for $1.8bn

Pharmaceutical Technology

AstraZeneca has signed a definitive agreement to buy US-based biopharmaceutical company CinCor Pharma in a deal valued at about $1.8bn. Under the deal, the company will initiate a tender offer to purchase all the outstanding shares of CinCor Pharma for $26 per share in cash.

article thumbnail

AstraZeneca makes CinCor Pharma acquisition

Pharma Times

Agreement involves access to global rights of blood pressure lowering therapy baxdrostat

109
109
article thumbnail

Bayer taps Google’s quantum power for drug discovery

Pharma Phorum

Bayer has signed an agreement with Google aimed at using high-level processing power to handle quantum chemistry calculations used to predict the chemical and physical properties of drug molecules at the atomic scale.

Protein 98
article thumbnail

AstraZeneca, Avillion get FDA approval for new ‘rescue’ drug for asthma

Bio Pharma Dive

Airsupra joins a growing portfolio of new drugs that are helping the British drugmaker offset wilting sales of older respiratory medicines like Pulmicort

article thumbnail

BioNTech to buy UK-based AI company InstaDeep

Pharmaceutical Technology

BioNTech has signed an agreement to buy UK-based artificial intelligence (AI) and machine learning (ML)-based products developer InstaDeep in a deal valued at about $440m (£362m) in cash and shares.

article thumbnail

Artificial pancreas technology set to change lives

Pharma Times

Emerging technology could help patients who are unable to manage their type 1 diabetes

108
108
article thumbnail

JPM23: Moderna reaped $18.4B in COVID vaccine sales last year, projects at least $5B in 2023

Fierce Pharma

JPM23: Moderna reaped $18.4B in COVID vaccine sales last year, projects at least $5B in 2023. kdunleavy. Mon, 01/09/2023 - 10:34

Sales 100
article thumbnail

Sanofi tops off venture arm, bringing fund to $750M

Bio Pharma Dive

The pharma is rolling out a multi-year capital commitment to its biotech investment group, which this week backed biotech NextPoint Therapeutics

258
258
article thumbnail

BARDA awards contract for Sabin’s Ebola Sudan and Marburg virus vaccines

Pharmaceutical Technology

The Biomedical Advanced Research and Development Authority (BARDA) has awarded a multi-year contract to the Sabin Vaccine Institute for developing and producing single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

article thumbnail

AlzeCure begins Alzheimer's therapy development phase

Pharma Times

Candidate will go through the development programme, which includes safety and tolerability studies

article thumbnail

AI and the Big Data paradigm – big ambitions in novel drug discovery

Pharma Phorum

Over the past few decades, data generation has veritably exploded. However, the ‘Big Data paradigm’ is not so much concerned with the volume of that data, but how businesses and, indeed, industries can derive meaningful insights from what has become a glut of information.

article thumbnail

HHS lays out timing for drug price negotiations

Bio Pharma Dive

The agency will kick off discussions on how it will negotiate Medicare drug prices in the spring and publish a list of the first 10 drugs selected by Sept. 1, 2023

Drugs 251
article thumbnail

AbbVie and Anima partner for mRNA biology modulators

Pharmaceutical Technology

AbbVie has collaborated with Anima Biotech for the discovery and development of mRNA biology modulators against three oncology and immunology targets.

article thumbnail

NHS Confederation responds to Prime Minister’s promise of NHS support

Pharma Times

New financial assistance emerges as UK Government announces imminent discharge fund

108
108